Q2 EBITDA 16% below ABGSCe on higher costsFY'23 production guidance lowered by ~5%Fair value range r...
Q2 report due on Thursday, 17 AugustEBIT down on lowered marginsHopefully more clarity on strategy w...
The required revaluation of a certain number of patients showed a high level of variability and this...
NoHo reported Q2 EBIT 13% above Vara consensus, despite 4% lower sales.
Redeye comments on Maximum Entertainment (prev Zordix) ahead of its Q2-results (due 16 August) where...
Infrea redovisade minskad omsättning och resultat i Q2 påverkat av kallare väder.
Q2 EBITDA 16% below ABGSCe on higher opexReduces FY'23 production guidance by ~5%Negative estimate c...
NoHo Partners reported Q2 EBIT of EUR 10.7m, +13% versus Vara consensus and +9% versus our estimate.
Redeye updates on EG7 ahead of its Q2-results (due 15 August) where we expect a seasonally softer su...
Redeye provides a preview of Thunderful Group ahead of its Q2 2023 report, due on August 21.
Tallinna Sadam will publish Q2 results on 10 August 2023.
Scanfil’s Q2 results were a bit better than we estimated.
XVIVO’s peer and future competitor TransMedics continues to open up the US Heart transplant market w...
Redeye provides an update in relation to Optomed’s Q2 2023 report.
Redeye provides an update on Physitrack ahead of its Q2’23-results (scheduled for 18 August), antici...
Good demand and high utilisation ratios were behind the record-breaking operating profit in Q2.
Redeye returns with an update following Annexin’s Q2 report.
Storbritannien visar fortsatt styrka mot en svagare nordisk marknad.
Redeye provides an initial take on Optomed’s Q2 2023 report.
Enersense’s Q2 results recovered well from the challenging comparison period, and earnings should ha...
